Corcept Therapeutics (CORT)
Health Care · biotechnology · NASDAQ
Corcept Therapeutics is a commercial-stage biotechnology company pioneering cortisol modulation therapies to treat severe endocrine, oncologic, and metabolic conditions.
What Corcept Therapeutics does
Corcept Therapeutics is a commercial-stage pharmaceutical company focused on the discovery and development of selective cortisol modulators to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders. The company markets Korlym and its authorized generic for the treatment of Cushing’s syndrome and Lifyorli (relacorilant) for the treatment of certain platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancers. Corcept also conducts extensive clinical research into the role of cortisol modulation in conditions such as difficult-to-control type 2 diabetes and resistant hypertension.
Themes: cortisol modulation, endocrinology, oncology, metabolic disorders, Cushing’s syndrome, rare diseases
Fundamentals
- Price$118.54 as of 2026-10-08 close
- Market cap$12.8B as of 2026-07-22 (share count; price 2026-10-08)
- 1-year return+34.0% 2025-10-08 close $88.43 → 2026-10-08 close $118.54
- P/E278.20 as of 2026-10-08
- Net margin+13.1% FY2025, SEC XBRL
- ROE+15.4% FY2025, SEC XBRL
- Debt / equity0.00 as of 2026-09-03
- Revenue growth (YoY)+16.0% as of 2026-09-03
- Revenue CAGR (3y)+23.7% SEC XBRL
- Beta1.18 as of 2026-09-03
- Last reported earnings2026-07-29 SEC EDGAR Form 8-K (Item 2.02)
How CORT compares in its sector
- price-to-earnings ratiotop 10% 185 covered Health Care peers, as of 2026-10-08
- net profit margintop 25% 430 covered Health Care peers, as of 2026-09-03
- operating marginmiddle range 417 covered Health Care peers, as of 2026-09-03
- return on equitytop 25% 510 covered Health Care peers, as of 2026-09-03
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)top 25% 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
CORT is not currently in any published Top 10 list. Its scores are below.
Top 10 score
Not scored for the top 10 list: it is in the most expensive tenth of the field on valuation, so it is ranked as a growth story rather than on fundamentals.
Scores as of 8 Oct 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 4.
How Corcept Therapeutics looks technically
Corcept Therapeutics (CORT) is trading 67.6% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 73 trading days ago — a "golden cross", a bullish long-term signal. A trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 24 (a reading of 25+ marks a strong trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 55, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bullish about 4 trading days ago (its momentum flipped positive). It made a new 20-day high about 4 trading days ago. Day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 9% of the past ~6 months), which often precedes a bigger move. Trading volume is unusually light — only about 34% of its 30-day average.
Trend
8
| Distance from the 200-day | it is trading 67.6% above its 200-day average, the long-term trend line — a longer-term uptrend | +67.6% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $115.12 | $115.12 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $70.72 | $70.72 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing low 30 calendar days ago — the swings before that are what the structure reading is measured on | 30 sessions |
| Wave structure | its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 5 of five; the labelling fails if price closes below 108.25. It is the only labelling that fits, and it describes the swings already printed, not what comes next. | possible upward five-wave sequence, in wave 5 |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 73 trading days ago — a "golden cross", a bullish long-term signal | 73 sessions |
| Trend strength (14-day ADX) | a trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 24 (a reading of 25+ marks a strong trend) | 24.0 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 55, neither overbought (above 70) nor oversold (below 30) | 55.5 |
|---|---|---|
| Position in its 14-day range | it is trading in the upper half of its 14-day range ($109.00 to $122.81) — its "stochastic" reading is 69 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 69.1 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 4 trading days ago (its momentum flipped positive) | 4 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $126.38 | $126.38 |
|---|---|---|
| From the 52-week high | it is 6.2% below its 52-week high (its highest price of the past year) | -6.2% |
| Above the 52-week low | it is 313.6% above its 52-week low (its lowest price of the past year) | +313.6% |
| Below the 52-week high | it is 6.2% below its highest point of the past year | 6.2% |
| Since a 20-day breakout | it made a new 20-day high about 4 trading days ago | 4 sessions |
| Since a 55-day breakout | it made a new 55-day high about 32 trading days ago | 32 sessions |
| All-time high | its highest closing price on record is $126.38 (set on 2026-08-25) | $126.38 |
| Given back of the 52-week move | over the past year its closes ranged ($32.15 to $123.57), and it has given back only a small part of its rise from last year’s low — 6% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $64.15 to $67.07. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 5.5% |
| From the all-time high | it is 6.2% below its all-time high | -6.2% |
| Nearest price level | it is trading 8.6% above a support level at $108.33 — a price it turned at twice since 2026-09-08, most recently on 2026-09-18. Since 2024-10-08 it has 11 such levels below the current price and 0 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -8.6% |
| All-time low | its lowest closing price on record is $0.68 (set on 2006-10-12) | $0.68 |
| Above the all-time low | it is 17332.4% above its all-time low | +17,332% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 9% of the past ~6 months), which often precedes a bigger move | 9th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $5.25 between its high and its low — about 4.4% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $5.25 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $109.09 and $121.59 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $109.09 – $115.34 – $121.59 |
| Typical daily range (% of price) | its price moves about 4.4% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 4.4% |
| Stretch from the 200-day average | it is trading 9.1 daily ranges above its 200-day average price (67.6% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 9.1 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is unusually light — only about 34% of its 30-day average | 0.34× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
1
| Since a doji | today it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | today |
|---|
Price gaps
3
| Gap at the open | it opened on 2026-10-08 0.9% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and had not traded back through that level by the close | -0.9% |
|---|---|---|
| Open gap | it gapped 20.5% above the previous close 49 sessions ago and has not traded back through the level it left behind at 92.95 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +20.5% |
| Gap filled | a 2.5% gap down opened on 2026-09-08 has been "filled" 22 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 22 sessions ago |
Price streaks
1
| Closing streak | it closed lower in its latest session, after a session that did not close lower — a single down day rather than a run | 1 session down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 3.0 percentage points (the stock gained 4.0% while the market gained 1.0%) | +3.0% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 23.7 percentage points (the stock gained 27.5% while the market gained 3.8%) | +23.7% |
| vs market, 6 months | over the past 6 months this stock beat the market by 172.7 percentage points (the stock gained 190.2% while the market gained 17.5%) | +172.7% |
| vs market, 12 months | over the past 12 months this stock beat the market by 19.1 percentage points (the stock gained 34.0% while the market gained 15.0%) | +19.1% |
Signal agreement
2
| Bullish technical signals | 5 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, MACD momentum is positive, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 5 of 9 |
|---|---|---|
| Bearish technical signals | 0 of the 9 technical signals we can compute for it are currently in a bearish state — these describe past price behaviour, not a forecast | 0 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 4.5% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is thick, spanning 9.8% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | +4.5% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 84% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $64.27 — a volume-weighted average of daily closes over 190 sessions, not a true tick-by-tick VWAP. | +84.4% |
|---|---|---|
| Vs the average paid since it last reported | the price is 4% above the average price paid since it last reported on 2026-07-29 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $113.49 — a volume-weighted average of daily closes over 51 sessions, not a true tick-by-tick VWAP. | +4.5% |
Head and shoulders, bearish — forming · entry $111.38 · 49 sessions in
Price levels it has turned at before
CORT last closed at $118.54 on 2026-10-08. Since 2024-10-08 it has turned at 11 prices below its last close and 0 above; the 3 nearest below are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $108.33 | Support | 8.6% below the last close | turned there twice · 2026-09-08 to 2026-09-18 |
| $89.50 | Support | 24.5% below the last close | turned there twice · 2025-12-15 to 2026-07-28 |
| $77.62 | Support | 34.5% below the last close | turned there three times · 2025-06-24 to 2026-06-22 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 5 of five.
This labelling fails — stops being a possible reading at all — if it closes below $108.25.
It is the only labelling that fits these swings, though its proportions are not the textbook ones. It was chosen from 3 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $119.19 and $136.90 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
This reading has stood for 14 trading days, since 2026-09-21.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · MACD just crossed bullish (12/26/9) · in a Bollinger Band volatility squeeze · beating the market · Printed a doji candle · Stretched far above its 200-day average (6+ daily ranges) | Learn: moving average · golden cross · adx · rsi · macd · breakout · bollinger bands · volume and relative volume
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (2.00 mean, 1=Strong Buy…5=Strong Sell) — 5 analysts
- Mean price target$141.00 range $50.00 – $165.00; median $164.00
Analyst estimates, as of 2026-10-08. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for CORT
- Consensus EPS estimate$0.865 next reporting period, as of 2026-10-08
- Estimate change, 30 days$0.00 (0.0%) from $0.865, on 2026-09-03, 35-day window
- Readings revised upward0% of 6 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Reliance on a limited number of commercial products, specifically Korlym and Lifyorli.","Risks associated with clinical trial outcomes and the ability to expand product indications into new therapeutic areas.","Potential impacts from regulatory scrutiny or changes in reimbursement policies for specialty drugs."]
What changed in the latest 10-Q
AI-assisted comparison of CORT's 10-Q filed 2026-07-29 against the prior one filed 2026-04-30.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-07-29) refers to 'our authorized generic version of Korlym' in the Hypercortisolism Products description.
- Newer filing (2026-07-29) states that the company uses Curant Health Georgia, LLC as the exclusive specialty pharmacy vendor to distribute Hypercortisolism Products directly to patients and provide logistical and pharmacy support, and uses a specialty distributor to distribute products to hospital pharmacies and other purchasers.
- Newer filing (2026-07-29) states that the MOMENTUM trial results presentation at the American College of Cardiology Annual Scientific Session occurred in March 2026 (the older filing stated "MOMENTUM’s results were presented at the American College of Cardiology Annual Scientific Session in March 2026"; the newer filing retains this statement).
- Newer filing (2026-07-29) states 'In April 2026, t' at the end of the provided text, indicating additional content not present in the older excerpt.
- Removed:
- Older filing (2026-04-30) describes the transition from Optime Care, Inc. to Curant Health Georgia, LLC: from 2017 to 2025 using Optime Care as exclusive specialty pharmacy vendor, June 2025 notification, October 2025 termination notice effective February 4, 2026, and transfer of specialty pharmacy services in the fourth quarter of 2025 and January and February 2026.
- Older filing (2026-04-30) states that CATALYST was conducted in 2023 and 2024.
- Reworded:
- Newer filing (2026-07-29) describes the generic version of Korlym as 'our authorized generic version' while the older filing (2026-04-30) describes it as 'a generic version of Korlym'.
- Newer filing (2026-07-29) condenses the specialty pharmacy and distribution description, removing the narrative of the Optime-to-Curant transition present in the older filing.
- Newer filing (2026-07-29) states the company 'initiated' the CATALYST study in 2023 without the phrase 'In 2023 and 2024, we conducted' used in the older filing.
- Notes:
- The newer filing text is truncated at the end ('In April 2026, t'), so content after that point cannot be compared.
- The older filing text is truncated at the end ('...our GRAD'), so content after that point cannot be compared.
Risk Factors
- Added:
- Newer filing (2026-07-29) in the 'factors that could limit product revenue' bullet list consolidates the preference for competing treatments into a single bullet referencing both 'patients with platinum-resistant ovarian cancer or hypercortisolism'.
- Removed:
- Older filing (2026-04-30) in the 'factors that could limit product revenue' bullet list contains two separate bullets: one for 'competing treatments for hypercortisolism' and one for 'competing treatments for platinum-resistant ovarian cancer'.
- Reworded:
- Newer filing (2026-07-29) removed the sentence 'Please see "Part II, Item 1, Legal Proceedings" for additional details.' that appeared in the older filing (2026-04-30) after the discussion of litigation settlements with Sun and Hikma.
- Notes:
- The newer filing text appears truncated in the final risk factor discussion; the older filing text also appears truncated at a similar point, so changes beyond the truncation point could not be assessed.
- Only the text provided was compared; no other sections of the filings were reviewed.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 64 open-market sales by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-04. The 5 days since 2026-10-04 have not been checked yet.
- Last 30 days · read to 2026-10-040 buys · 15 sells ($7M) — 4 selling insiders
- Last 90 days · read to 2026-10-040 buys · 64 sells ($57M) — 9 selling insiders
- Last 180 days · read to 2026-10-040 buys · 86 sells ($82M) — 10 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-10-02. Based on Form 4 filings read through 2026-10-04; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about CORT's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
6 institutional 13F filers reported holding CORT as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 6
- Reported shares held 25,219,662
- Reported value $2,192,857,911
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 5 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about CORT's institutional holders → See what each manager we track holds →
Short interest (FINRA)
CORT had 9,350,914 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
CORT had 8.65% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 9.91 days to cover at the same settlement.
- Reported short interest (shares) 9,350,914
- Short interest (% of shares outstanding) 8.65%
- Prior settlement (shares) 9,399,154
- Reported change -0.51%
- Days to cover (reported) 9.91
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Amgen (AMGN)
- Bristol Myers Squibb (BMY)
- Novartis (NVS)
- Ipsen (IPSEY)
- Recordati (RCDBY)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare CORT vs…
Corcept Therapeutics is found in…
CORT ranks in…
Frequently asked questions
What does Corcept Therapeutics (CORT) do?
Corcept Therapeutics is a commercial-stage pharmaceutical company focused on the discovery and development of selective cortisol modulators to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders. The company markets Korlym and its authorized generic for the treatment of Cushing’s syndrome and Lifyorli (relacorilant) for the treatment of certain platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancers.
What sector is Corcept Therapeutics (CORT) in?
Corcept Therapeutics (CORT) is classified in the Health Care sector. Its industry is biotechnology. It trades on NASDAQ.
Who are Corcept Therapeutics's (CORT) competitors?
Notable peers of Corcept Therapeutics (CORT) include Amgen, Bristol Myers Squibb, Novartis, Ipsen and Recordati. This peer set is informational only — not financial advice.
Is Corcept Therapeutics (CORT) overbought or oversold right now?
Corcept Therapeutics (CORT) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 55, in the neutral middle (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on CORT come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.